%0 Journal Article %1 Deprimo.2006 %A Deprimo, S. E. %A Friece, C. %A Huang, X. %A Smeraglia, J. %A Sherman, L. %A Collier, M. %A Baum, C. %A Elias, A. D. %A Burstein, H. J. %A Miller, K. D. %D 2006 %J J Clin Oncol (Meeting Abstracts) %K Outcome Proteins Research SU11248 Treatment Tyrosine analysis methods protein response therapy %N 18_suppl %P 578 %T Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer %U http://meeting.jco.org/cgi/content/abstract/24/18_suppl/578 %V 24 %X 578 Background: Sunitinib malate (SU11248) is a multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity that specifically inhibits VEGFR, PDGFR, KIT, RET and FLT3. In a phase II trial of 64 patients with refractory, metastatic breast cancer, sunitinib treatment resulted in an ~11% objective response rate (Miller et al, ASCO 2005). To characterize potential biomarkers of biological response to sunitinib, we analyzed plasma levels of a panel of soluble proteins from patients in this trial. Methods: Patients received sunitinib in 6-week cycles comprised of 50 mg/day for 4 weeks followed by 2 weeks off treatment. Pre-dose plasma samples from 62 patients were obtained on days 1, 14, and 28 of the first cycle and days 1 and 28 of subsequent cycles. Plasma levels of VEGF, soluble VEGF receptor 2 (sVEGFR-2), soluble KIT (sKIT), and a novel biomarker, sVEGFR-3, were measured via ELISA analysis. Results: Plasma levels of each protein were modulated in most patients d

@article{Deprimo.2006, abstract = {578 Background: Sunitinib malate (SU11248) is a multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity that specifically inhibits VEGFR, PDGFR, KIT, RET and FLT3. In a phase II trial of 64 patients with refractory, metastatic breast cancer, sunitinib treatment resulted in an [~]11% objective response rate (Miller et al, ASCO 2005). To characterize potential biomarkers of biological response to sunitinib, we analyzed plasma levels of a panel of soluble proteins from patients in this trial. Methods: Patients received sunitinib in 6-week cycles comprised of 50 mg/day for 4 weeks followed by 2 weeks off treatment. Pre-dose plasma samples from 62 patients were obtained on days 1, 14, and 28 of the first cycle and days 1 and 28 of subsequent cycles. Plasma levels of VEGF, soluble VEGF receptor 2 (sVEGFR-2), soluble KIT (sKIT), and a novel biomarker, sVEGFR-3, were measured via ELISA analysis. Results: Plasma levels of each protein were modulated in most patients d}, added-at = {2010-02-05T11:28:39.000+0100}, author = {Deprimo, S. E. and Friece, C. and Huang, X. and Smeraglia, J. and Sherman, L. and Collier, M. and Baum, C. and Elias, A. D. and Burstein, H. J. and Miller, K. D.}, biburl = {https://www.bibsonomy.org/bibtex/2c051401322a1f486c5abd101be04bb7c/kanefendt}, interhash = {78b24b80153edacd7fb67e831ddd9806}, intrahash = {c051401322a1f486c5abd101be04bb7c}, journal = {J Clin Oncol (Meeting Abstracts)}, keywords = {Outcome Proteins Research SU11248 Treatment Tyrosine analysis methods protein response therapy}, number = {18_suppl}, pages = 578, timestamp = {2010-02-05T11:28:54.000+0100}, title = {Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer}, url = {http://meeting.jco.org/cgi/content/abstract/24/18_suppl/578}, volume = 24, year = 2006 }